Clinical trial results:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study Investigating the Efficacy and Safety of PF-04965842 Co-administered With Background Medicated Topical Therapy in Adolescent Participants 12 to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Summary

EudraCT number	2018-003804-37
Trial protocol	HU CZ LV PL GB DE IT
Global end of trial date	08 April 2020

Results information

Result version number	v1 (current)
This version publication date	17 October 2020
First version publication date	17 October 2020

Trial information

Trial identification

Sponsor protocol code	B7451036

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03796676
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer, Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., +1 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., +1 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 September 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	08 April 2020
Global end of trial reached?	Yes
Global end of trial date	08 April 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective was to assess the efficacy of PF-04965842 compared with placebo when coadministered with background medicated topical therapy in adolescent subjects 12 to <18 years of age with moderate-to-severe atopic dermatitis (AD).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy:

Medicated topical therapy (topical corticosteroid or topical calcineurin inhibitors or phosphodiesterase type 4 [PDE4] inhibitor)

Evidence for comparator: -

Actual start date of recruitment	18 February 2019
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	24 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 9
Country: Number of subjects enrolled	China: 52
Country: Number of subjects enrolled	Czech Republic: 4
Country: Number of subjects enrolled	Germany: 6
Country: Number of subjects enrolled	Hungary: 17
Country: Number of subjects enrolled	Italy: 2
Country: Number of subjects enrolled	Japan: 26
Country: Number of subjects enrolled	Latvia: 2
Country: Number of subjects enrolled	Mexico: 23
Country: Number of subjects enrolled	Poland: 43
Country: Number of subjects enrolled	Spain: 13
Country: Number of subjects enrolled	Taiwan: 8
Country: Number of subjects enrolled	United States: 80
Worldwide total number of subjects	285
EEA total number of subjects	87

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	1
Adolescents (12-17 years)	283
Adults (18-64 years)	1
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 408 subjects were screened, 287 subjects were enrolled and assigned to 1 of 3 treatments. Only 285 subjects received the study treatment and 2 subjects withdrew prior to dosing.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	PF-04965842 100mg QD

Arm description:

Subjects in this treatment group received PF-04965842 100 mg once daily (QD) for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	PF-04965842
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 1 tablet of PF-04965842 100 mg and 1 tablet of placebo QD.

Arm title	PF-04965842 200mg QD

Arm description:

Subjects in this treatment group received PF-04965842 200 mg QD for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	PF-04965842
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 2 tablets of PF-04965842 100 mg QD.

Arm title	Placebo

Arm description:

Subjects in this treatment group received PF-04965842-matching placebo QD for 12 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:
Subjects received 2 tablets of PF-04965842 matching placebo QD.

Number of subjects in period 1	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo
Started	95	94	96
Completed	92	91	90
Not completed	3	3	6
Adverse event, non-fatal	1	2	2
Withdrawal by Parent/Guardian	1	-	1
Lost to follow-up	1	-	2
COVID-19 impact	-	-	1
Protocol deviation	-	1	-

Baseline characteristics

Reporting groups	
Reporting group title	Overall Study
Reporting group description:	
Subjects received QD PF-04965842 at 200 mg, 100 mg or placebo for 12 weeks.	

Reporting group values	Overall Study	Total	
Number of subjects	285	285	
Age Categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	1	1	
Adolescents (12-17 years)	283	283	
Adults (18-64 years)	1	1	
From 65-84 years	0	0	
85 years and over	0	0	
Age Continuous Units: years			
median	15		
full range (min-max)	11 to 18	-	
Gender Categorical Units: Subjects			
Female	140	140	
Male	145	145	
Race Units: Subjects			
White	160	160	
Black or African American	17	17	
Asian	94	94	
American Indian or Alaska Native	8	8	
Native Hawaiian or Other Pacific Islander	2	2	
Multiracial	2	2	
Not reported	2	2	

End points

End points reporting groups

Reporting group title	PF-04965842 100mg QD
Reporting group description:	
Subjects in this treatment group received PF-04965842 100 mg once daily (QD) for 12 weeks.	
Reporting group title	PF-04965842 200mg QD
Reporting group description:	
Subjects in this treatment group received PF-04965842 200 mg QD for 12 weeks.	
Reporting group title	Placebo
Reporting group description:	
Subjects in this treatment group received PF-04965842-matching placebo QD for 12 weeks.	

Primary: Proportion of Subjects Achieving Investigator's Global Assessment (IGA) Response of "Clear" (0) or "Almost Clear" (1) and >=2 Points Improvement from Baseline at Week 12

End point title	Proportion of Subjects Achieving Investigator's Global Assessment (IGA) Response of "Clear" (0) or "Almost Clear" (1) and >=2 Points Improvement from Baseline at Week 12
End point description:	
The IGA of AD is scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD were assessed according to a 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Subjects who withdrew from the study were counted as non-responder. The analysis of this endpoint were performed using the full analysis set (FAS) which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.	
End point type	Primary
End point timeframe:	
Baseline to Week 12	

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	89	93	94	
Units: Percent of total evaluable subjects				
number (confidence interval 95%)	41.6 (31.3 to 51.8)	46.2 (36.1 to 56.4)	24.5 (15.8 to 33.2)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo
Comparison groups	PF-04965842 100mg QD v Placebo

Number of subjects included in analysis	183
Analysis specification	Pre-specified
Analysis type	superiority[1]
P-value	= 0.0147 [2]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Estimate of difference
Point estimate	16.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.5
upper limit	29.9

Notes:

[1] - Estimate of the difference in proportions of response was calculated by PF-04965842 100 mg minus placebo
[2] - The significance level is 0.05.

Statistical analysis title	PF-04965842 200 mg Versus Placebo
Comparison groups	PF-04965842 200mg QD v Placebo
Number of subjects included in analysis	187
Analysis specification	Pre-specified
Analysis type	superiority[3]
P-value	= 0.003 [4]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Estimate of difference
Point estimate	20.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.3
upper limit	33.9

Notes:

[3] - Estimate of the difference in proportions of response was calculated by PF-04965842 200 mg minus placebo
[4] - The significance level is 0.05.

Primary: Proportion of Subjects Achieving Eczema Area and Severity Index (EASI) Response >= 75% Improvement from Baseline at Week 12

End point title	Proportion of Subjects Achieving Eczema Area and Severity Index (EASI) Response >= 75% Improvement from Baseline at Week 12

End point description:

The EASI quantifies the severity of a subject’s AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Subjects who withdrew from the study were counted as non-responder. The analysis of this endpoint was performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Primary

End point timeframe:

Baseline to Week 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	89	93	94	
Units: Percent of total evaluable subjects				
number (confidence interval 95%)	68.5 (58.9 to 78.2)	72.0 (62.9 to 81.2)	41.5 (31.5 to 51.4)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo
Comparison groups	PF-04965842 100mg QD v Placebo
Number of subjects included in analysis	183
Analysis specification	Pre-specified
Analysis type	superiority[5]
P-value	= 0.0002 [6]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Estimate of difference
Point estimate	26.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	13.1
upper limit	39.8

Notes:

[5] - Estimate of the difference in proportions of response was calculated by PF-04965842 100 mg minus placebo
[6] - The significance level is 0.05.

Statistical analysis title	PF-04965842 200 mg Versus Placebo
Comparison groups	PF-04965842 200mg QD v Placebo
Number of subjects included in analysis	187
Analysis specification	Pre-specified
Analysis type	superiority[7]
P-value	< 0.0001 [8]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Estimate of difference
Point estimate	29.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	16.3
upper limit	42.5

Notes:

[7] - Estimate of the difference in proportions of response was calculated by PF-04965842 200 mg minus placebo
[8] - The significance level is 0.05.

Secondary: Proportion of Subjects Achieving >=4 Points Improvement from Baseline in Peak Pruritis Numeric Rating Scale (PP-NRS) for Severity of Pruritus at Weeks 2, 4 and 12

End point title	Proportion of Subjects Achieving >=4 Points Improvement from Baseline in Peak Pruritis Numeric Rating Scale (PP-NRS) for Severity of Pruritus at Weeks 2, 4 and 12

End point description:

PP-NRS assesses the severity of itch (pruritus) due to AD. Subjects were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Subjects who withdrew from the study were counted as non-responder. The analysis of this endpoint was performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent of total evaluable subjects				
number (confidence interval 95%)				
Week 2	27.2 (18.1 to 36.3)	38.6 (28.5 to 48.8)	12.6 (6.0 to 19.3)	
Week 4	31.5 (21.8 to 41.1)	50.0 (39.3 to 60.7)	20.7 (12.4 to 28.9)	
Week 12	52.6 (41.4 to 63.9)	55.4 (44.1 to 66.7)	29.8 (20.0 to 39.5)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Palcebo at Week2
Comparison groups	PF-04965842 100mg QD v Placebo
Number of subjects included in analysis	191
Analysis specification	Pre-specified
Analysis type	superiority[9]
P-value	= 0.0119 [10]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Estimate of difference
Point estimate	14.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.5
upper limit	25.9

Notes:

[9] - Estimate of the difference in proportions of response was calculated by PF-04965842 100 mg minus placebo
[10] - The significance level is 0.05.

Statistical analysis title	PF-04965842 200 mg Versus Placebo at Week 2
Comparison groups	PF-04965842 200mg QD v Placebo

Number of subjects included in analysis	190
Analysis specification	Pre-specified
Analysis type	superiority[11]
P-value	< 0.0001 [12]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Estimate of difference
Point estimate	26.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	13.9
upper limit	38.3

Notes:

[11] - Estimate of the difference in proportions of response was calculated by PF-04965842 200 mg minus placebo
[12] - The significance level is 0.05.

Statistical analysis title	PF-04965842 100 mg Versus Placebo at Week 4
Comparison groups	PF-04965842 100mg QD v Placebo
Number of subjects included in analysis	191
Analysis specification	Pre-specified
Analysis type	superiority[13]
P-value	= 0.0971 [14]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Estimate of difference
Point estimate	10.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	23.6

Notes:

[13] - Estimate of the difference in proportions of response was calculated by PF-04965842 100 mg minus placebo
[14] - The significance level is 0.05.

Statistical analysis title	PF-04965842 200 mg Versus Placebo at Week 4
Comparison groups	PF-04965842 200mg QD v Placebo
Number of subjects included in analysis	190
Analysis specification	Pre-specified
Analysis type	superiority[15]
P-value	< 0.0001 [16]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Estimate of difference
Point estimate	29.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	16
upper limit	42.9

Notes:

[15] - Estimate of the difference in proportions of response was calculated by PF-04965842 200 mg minus placebo
[16] - The significance level is 0.05.

Statistical analysis title	PF-04965842 100 mg Versus Placebo at Week 12
Comparison groups	PF-04965842 100mg QD v Placebo
Number of subjects included in analysis	191
Analysis specification	Pre-specified
Analysis type	superiority[17]
P-value	= 0.0035 [18]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Estimate of difference
Point estimate	22.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	8
upper limit	37.7

Notes:

[17] - Estimate of the difference in proportions of response was calculated by PF-04965842 100 mg minus placebo
[18] - It is considered not statistically significant according to the sequential Bonferronibased iterative multiple testing procedure.

Statistical analysis title	PF-04965842 200 mg Versus Placebo at Week 12
Comparison groups	PF-04965842 200mg QD v Placebo
Number of subjects included in analysis	190
Analysis specification	Pre-specified
Analysis type	superiority[19]
P-value	= 0.0013 [20]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Estimate of difference
Point estimate	25.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.6
upper limit	40.6

Notes:

[19] - Estimate of the difference in proportions of response was calculated by PF-04965842 200 mg minus placebo
[20] - The significance level is 0.05.

Secondary: Change from Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) at Week 12

End point title	Change from Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) at Week 12

End point description:

The PSAAD is a 15 item questionnaire that includes 11 items developed to measure symptoms of AD based on a 24 hour recall. Four additional items were added for exploratory and psychometric validation purposes (Sleep & Usual Activities Questions and Patient Global Impression of Severity & Patient Global Impression of Change Questions). The analysis of this endpoint were performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:
Baseline to Week 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	93	95	
Units: Units on a scale				
least squares mean (confidence interval 95%)	-2.5 (-2.9 to -2.1)	-2.7 (-3.1 to -2.3)	-2.0 (-2.4 to -1.6)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo
Comparison groups	PF-04965842 100mg QD v Placebo
Number of subjects included in analysis	190
Analysis specification	Pre-specified
Analysis type	superiority[21]
P-value	= 0.0664 [22]
Method	Mixed models analysis
Parameter estimate	Mean difference (net)
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	0

Notes:
[21] - The least squares mean difference was calculated by PF-04965842 100 mg minus placebo.
[22] - The significance level is 0.05.

Statistical analysis title	PF-04965842 200 mg Versus Placebo
Comparison groups	PF-04965842 200mg QD v Placebo
Number of subjects included in analysis	188
Analysis specification	Pre-specified
Analysis type	superiority[23]
P-value	= 0.0142 [24]
Method	Mixed models analysis
Parameter estimate	Mean difference (net)
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	-0.1

Notes:

[23] - The least squares mean difference was calculated by PF-04965842 200 mg minus placebo.

[24] - It is considered not statistically significant according to the sequential Bonferronibased iterative multiple testing procedure.

Secondary: Proportion of Subjects Achieving IGA Response of 'Clear'(0) or 'Almost Clear'(1) and >=2 Points Improvement from Baseline at All Scheduled Time Points Except Week 12

End point title	Proportion of Subjects Achieving IGA Response of 'Clear'(0) or 'Almost Clear'(1) and >=2 Points Improvement from Baseline at All Scheduled Time Points Except Week 12

End point description:

The IGA of AD is scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD were assessed according to a 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Subjects who withdrew from the study were counted as non-responder. The analysis of this endpoint were performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, and 8

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent of total evaluable subjects				
number (confidence interval 95%)				
Week 2	6.5 (1.5 to 11.6)	12.8 (6.0 to 19.5)	1.1 (0.0 to 3.2)	
Week 4	19.6 (11.5 to 27.7)	38.3 (28.5 to 48.1)	3.1 (0.0 to 6.6)	
Week 8	30.8 (21.3 to 40.3)	48.9 (38.7 to 59.1)	16.0 (8.6 to 23.4)	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects Achieving EASI Response >= 75% Improvement from Baseline at All Scheduled Time Points Except Week 12

End point title	Proportion of Subjects Achieving EASI Response >= 75% Improvement from Baseline at All Scheduled Time Points Except Week 12

End point description:

The EASI quantifies the severity of a subject’s AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0 to 72.0, with higher scores representing greater severity of AD. Subjects who withdrew from the study were counted as non-responder. The analysis of this endpoint was performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4 and 8

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent of total evaluable subjects				
number (confidence interval 95%)				
Week 2	19.6 (11.5 to 27.7)	25.5 (16.7 to 34.3)	4.4 (0.2 to 8.6)	
Week 4	41.3 (31.2 to 51.4)	63.8 (54.1 to 73.5)	14.6 (7.5 to 21.6)	
Week 8	60.4 (50.4 to 70.5)	68.5 (59.0 to 78.0)	33.3 (23.8 to 42.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects Achieving EASI Response >= 50% Improvement from Baseline

End point title	Proportion of Subjects Achieving EASI Response >= 50% Improvement from Baseline

End point description:

The EASI quantifies the severity of a subject’s AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0 to 72.0, with higher scores representing greater severity of AD. Subjects who withdrew from the study were counted as non-responder. The analysis of this endpoint was performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent of total evaluable subjects				
number (confidence interval 95%)				
Week 2	55.4 (45.3 to 65.6)	64.9 (55.2 to 74.5)	24.2 (15.4 to 33.0)	
Week 4	75.0 (66.2 to 83.8)	81.9 (74.1 to 89.7)	51.0 (41.0 to 61.0)	
Week 8	85.7 (78.5 to 92.9)	82.6 (74.9 to 90.4)	65.6 (55.9 to 75.2)	

Week 12	87.6 (80.8 to 94.5)	87.1 (80.3 to 93.9)	69.1 (59.8 to 78.5)	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects Achieving EASI Response >= 90% Improvement from Baseline

End point title	Proportion of Subjects Achieving EASI Response >= 90% Improvement from Baseline

End point description:

The EASI quantifies the severity of a subject's AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0 to 72.0, with higher scores representing greater severity of AD. Subjects who withdrew from the study were counted as non-responder. The analysis of this endpoint was performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent of total evaluable subjects				
number (confidence interval 95%)				
Week 2	8.7 (2.9 to 14.5)	10.6 (4.4 to 16.9)	0 (0.0 to 4.0)	
Week 4	17.4 (9.6 to 25.1)	30.9 (21.5 to 40.2)	2.1 (0.0 to 4.9)	
Week 8	29.7 (20.3 to 39.1)	40.2 (30.2 to 50.2)	14.0 (6.9 to 21.0)	
Week 12	41.6 (31.3 to 51.8)	49.5 (39.3 to 59.6)	18.1 (10.3 to 25.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects Achieving EASI Response = 100% Improvement from Baseline

End point title	Proportion of Subjects Achieving EASI Response = 100% Improvement from Baseline

End point description:

The EASI quantifies the severity of a subject's AD based on both severity of lesion clinical signs and the

percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0 to 72.0, with higher scores representing greater severity of AD. Subjects who withdrew from the study were counted as non-responder. The analysis of this endpoint was performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent of total evaluable subjects				
number (confidence interval 95%)				
Week 2	1.1 (0.0 to 3.2)	0 (0.0 to 3.8)	0 (0.0 to 4.0)	
Week 4	2.2 (0.0 to 5.2)	5.3 (0.8 to 9.9)	0 (0.0 to 3.8)	
Week 8	3.3 (0.0 to 7.0)	9.8 (3.7 to 15.9)	0 (0.0 to 3.9)	
Week 12	2.2 (0.0 to 5.3)	8.6 (2.9 to 14.3)	2.1 (0.0 to 5.0)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change from Baseline in EASI Score

End point title	Percent Change from Baseline in EASI Score

End point description:

The EASI quantifies the severity of a subject’s AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. The analysis of this endpoint was performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8 and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent change				
least squares mean (confidence interval 95%)				
Week 2	-51.5 (-57.9 to -45.1)	-54.5 (-61.0 to -48.0)	-27.6 (-34.0 to -21.2)	

Week 4	-66.1 (-72.7 to -59.4)	-74.3 (-81.0 to -67.5)	-41.7 (-48.3 to -35.1)	
Week 8	-72.6 (-78.4 to -66.8)	-77.8 (-83.7 to -71.9)	-57.6 (-63.4 to -51.8)	
Week 12	-77.3 (-83.1 to -71.5)	-80.6 (-86.5 to -74.8)	-63.7 (-69.5 to -57.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects Achieving >=4 Points Improvement from Baseline in PP-NRS or Severity of Pruritus at All Scheduled Time Points Other Than Weeks 2, 4 and 12

End point title	Proportion of Subjects Achieving >=4 Points Improvement from Baseline in PP-NRS or Severity of Pruritus at All Scheduled Time Points Other Than Weeks 2, 4 and 12

End point description:

PP-NRS assesses the severity of itch (pruritus) due to AD. Subjects were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Subjects who withdrew from the study were counted as non-responder. The analysis of this endpoint was performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent of total evaluable subjects				
number (confidence interval 95%)				
Day 2	2.8 (0.0 to 6.7)	3.9 (0.0 to 8.2)	1.2 (0.0 to 3.6)	
Day 3	5.1 (0.2 to 9.9)	7.7 (1.8 to 13.6)	0 (0.0 to 4.6)	
Day 4	11.5 (4.4 to 18.6)	14.3 (6.5 to 22.1)	4.9 (0.2 to 9.7)	
Day 5	12.2 (5.1 to 19.3)	18.5 (10.1 to 27.0)	6.9 (1.1 to 12.8)	
Day 6	16.0 (8.1 to 24.0)	21.3 (12.3 to 30.2)	8.8 (2.6 to 14.9)	
Day 7	16.0 (8.1 to 24.0)	21.3 (12.3 to 30.2)	10.1 (3.5 to 16.8)	
Day 8	17.3 (8.8 to 25.9)	25.0 (15.3 to 34.7)	4.0 (0.0 to 8.4)	
Day 9	16.0 (7.7 to 24.3)	25.0 (15.5 to 34.5)	6.0 (0.9 to 11.1)	
Day 10	15.6 (7.5 to 23.7)	28.8 (18.8 to 38.7)	8.3 (2.4 to 14.2)	
Day 11	20.8 (11.7 to 29.8)	27.0 (16.9 to 37.1)	7.6 (1.8 to 13.4)	

Day 12	22.2 (12.6 to 31.8)	23.6 (13.8 to 33.4)	10.8 (3.7 to 17.9)	
Day 13	26.3 (16.6 to 35.9)	31.2 (20.8 to 41.5)	10.0 (3.4 to 16.6)	
Day 14	24.7 (15.3 to 34.1)	32.4 (21.8 to 43.1)	9.5 (3.2 to 15.8)	
Day 15	27.7 (18.1 to 37.3)	37.8 (27.3 to 48.3)	14.3 (6.8 to 21.8)	

Statistical analyses

No statistical analyses for this end point

Secondary: Time to First Achieve >=4 Points Improvement from Baseline in PP-NRS for Severity of Pruritus

End point title	Time to First Achieve >=4 Points Improvement from Baseline in PP-NRS for Severity of Pruritus

End point description:

PP-NRS assesses the severity of itch (pruritus) due to AD. Subjects were asked to assess their worst itching due to AD on an NRS anchored by the terms “no itch” (0) and “worst itch imaginable” (10). Subjects from FAS population with a baseline numeric rating scale score for severity of pruritus >=4 were included in the analysis. "99999" represents "non-evaluable" datum.

End point type	Secondary

End point timeframe:

Baseline to Week 16

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Days				
median (confidence interval 95%)	70.0 (30.0 to 85.0)	29.0 (15.0 to 61.0)	90.0 (62.0 to 99999)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change from Baseline in PP-NRS for Severity of Pruritus

End point title	Percent Change from Baseline in PP-NRS for Severity of Pruritus

End point description:

PP-NRS assesses the severity of itch (pruritus) due to AD. Subjects were asked to assess their worst itching due to AD on an NRS anchored by the terms “no itch” (0) and “worst itch imaginable” (10). The analysis of this endpoint was performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent Change				
least squares mean (confidence interval 95%)				
Day 2	-9.5 (-14.2 to -4.8)	-5.4 (-10.0 to -0.7)	-0.9 (-5.5 to 3.6)	
Day 3	-11.3 (-16.2 to -6.4)	-10.2 (-15.2 to -5.2)	-1.1 (-6.0 to 3.8)	
Day 4	-14.6 (-20.2 to -9.1)	-14.7 (-20.3 to -9.1)	-5.0 (-10.6 to 0.5)	
Day 5	-16.1 (-22.3 to -9.9)	-17.6 (-23.9 to -11.3)	-9.5 (-15.8 to -3.2)	
Day 6	-18.5 (-25.0 to -12.1)	-18.7 (-25.3 to -12.1)	-8.7 (-15.2 to -2.2)	
Day 7	-20.0 (-27.1 to -12.9)	-18.8 (-26.0 to -11.6)	-12.3 (-19.4 to -5.2)	
Day 8	-21.6 (-28.9 to -14.2)	-22.7 (-30.2 to -15.3)	-10.6 (-17.9 to -3.3)	
Day 9	-20.9 (-28.7 to -13.2)	-21.7 (-29.5 to -13.9)	-9.9 (-17.6 to -2.3)	
Day 10	-26.1 (-33.1 to -19.0)	-28.0 (-35.1 to -20.8)	-10.8 (-17.8 to -3.8)	
Day 11	-26.5 (-33.5 to -19.4)	-26.3 (-33.5 to -19.1)	-10.7 (-17.7 to -3.7)	
Day 12	-27.0 (-34.0 to -20.0)	-28.9 (-36.1 to -21.8)	-11.0 (-18.0 to -4.0)	
Day 13	-25.2 (-31.5 to -18.8)	-32.5 (-39.0 to -26.0)	-14.1 (-20.4 to -7.8)	
Day 14	-29.4 (-35.5 to -23.2)	-35.3 (-41.6 to -29.0)	-12.0 (-18.1 to -5.8)	
Day 15	-30.7 (-37.7 to -23.7)	-33.4 (-40.5 to -26.3)	-15.8 (-22.7 to -8.8)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Percentage Body Surface Area (BSA)

End point title	Change from Baseline in Percentage Body Surface Area (BSA)

End point description:

BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual subject for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible value was less than 100%. The analysis of this endpoint was performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8 and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Units on a scale				
least squares mean (confidence interval 95%)				
Week 2	-21.0 (-24.1 to -17.9)	-20.7 (-23.8 to -17.6)	-10.9 (-14.0 to -7.8)	
Week 4	-27.7 (-31.0 to -24.3)	-32.6 (-36.0 to -29.1)	-15.1 (-18.4 to -11.7)	
Week 8	-32.6 (-36.1 to -29.1)	-34.1 (-37.7 to -30.6)	-21.8 (-25.3 to -18.3)	
Week 12	-34.4 (-38.0 to -30.8)	-35.2 (-38.8 to -31.6)	-24.2 (-27.8 to -20.7)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change from Baseline in Percentage BSA

End point title	Percent Change from Baseline in Percentage BSA

End point description:

BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual subject for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of atopic dermatitis. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible value was less than 100%. The analysis of this endpoint was performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent change				
least squares mean (confidence interval 95%)				
Week 2	-40.4 (-46.5 to -34.3)	-42.2 (-48.3 to -36.1)	-20.6 (-26.7 to -14.5)	

Week 4	-55.4 (-62.7 to -48.1)	-66.0 (-73.4 to -58.6)	-29.0 (-36.3 to -21.8)	
Week 8	-65.7 (-72.4 to -59.1)	-69.5 (-76.3 to -62.8)	-46.0 (-52.6 to -39.3)	
Week 12	-71.4 (-78.2 to -64.7)	-72.6 (-79.3 to -65.8)	-53.4 (-60.1 to -46.7)	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects Achieving Percentage BSA < 5% at Week 12

End point title	Proportion of Subjects Achieving Percentage BSA < 5% at Week 12

End point description:

BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual subject for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of atopic dermatitis. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible value was less than 100%. Subjects who withdrew from the study were counted as non-responder. The analysis of this endpoint was performed using the FAS which was defined as all subjects randomly assigned to study intervention and who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline to Week 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	89	93	94	
Units: Percent of evaluable subjects				
number (confidence interval 95%)	38.2 (28.1 to 48.3)	36.6 (26.8 to 46.3)	24.5 (15.8 to 33.2)	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects Achieving Scoring Atopic Dermatitis (SCORAD) Response >= 50% Improvement from Baseline

End point title	Proportion of Subjects Achieving Scoring Atopic Dermatitis (SCORAD) Response >= 50% Improvement from Baseline

End point description:

SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the subject using a NRS where “0” is no itch (or no sleeplessness) and “10” is the worst imaginable itch (or

sleeplessness).These scores are added to give 'C' (maximum of 20).The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent of evaluable subjects				
number (confidence interval 95%)				
Week 2	22.6 (14.1 to 31.1)	29.0 (19.8 to 38.3)	8.6 (2.9 to 14.3)	
Week 4	44.1 (34.0 to 54.2)	64.1 (54.3 to 73.9)	24.0 (15.4 to 32.5)	
Week 8	65.6 (55.9 to 75.2)	75.0 (66.2 to 83.8)	34.0 (24.5 to 43.6)	
Week 12	75.6 (66.7 to 84.4)	73.9 (64.9 to 82.9)	37.6 (27.8 to 47.5)	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects Achieving SCORAD Response >= 75% Improvement from Baseline

End point title	Proportion of Subjects Achieving SCORAD Response >= 75% Improvement from Baseline

End point description:

SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject using a NRS where “0” is no itch (or no sleeplessness) and “10” is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent of evaluable subjects				
number (confidence interval 95%)				
Week 2	5.4 (0.8 to 10.0)	7.5 (2.2 to 12.9)	0 (0.0 to 3.9)	
Week 4	11.8 (5.3 to 18.4)	21.7 (13.3 to 30.2)	0 (0.0 to 3.8)	
Week 8	17.2 (9.5 to 24.9)	33.7 (24.0 to 43.4)	8.5 (2.9 to 14.2)	
Week 12	36.7 (26.7 to 46.6)	34.8 (25.1 to 44.5)	12.9 (6.1 to 19.7)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in SCORAD Total Score

End point title	Change from Baseline in SCORAD Total Score

End point description:

SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	93	96	
Units: Units on a scale				
least squares mean (confidence interval 95%)				
Week 2	-24.6 (-27.7 to -21.6)	-25.8 (-28.9 to -22.7)	-12.3 (-15.4 to -9.2)	
Week 4	-32.4 (-35.5 to -29.2)	-38.0 (-41.2 to -34.8)	-20.2 (-23.3 to -17.0)	
Week 8	-37.3 (-40.7 to -33.9)	-41.5 (-45.0 to -38.0)	-26.6 (-30.0 to -23.2)	
Week 12	-40.9 (-44.7 to -37.2)	-42.9 (-46.7 to -39.1)	-30.2 (-33.9 to -26.4)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change from Baseline in SCORAD Total Score

End point title	Percent Change from Baseline in SCORAD Total Score

End point description:

SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	93	96	
Units: Percent change				
least squares mean (confidence interval 95%)				
Week 2	-36.1 (-40.6 to -31.7)	-38.7 (-43.2 to -34.2)	-18.7 (-23.1 to -14.2)	
Week 4	-47.4 (-52.0 to -42.9)	-56.9 (-61.6 to -52.3)	-30.0 (-34.5 to -25.5)	
Week 8	-54.0 (-59.0 to -48.9)	-62.0 (-67.2 to -56.9)	-39.9 (-44.9 to -34.8)	
Week 12	-59.2 (-64.9 to -53.6)	-64.3 (-70.1 to -58.6)	-44.4 (-50.1 to -38.8)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in SCORAD Subjective Visual Analogue Scale (VAS) of Sleep Loss and Itch

End point title	Change from Baseline in SCORAD Subjective Visual Analogue Scale (VAS) of Sleep Loss and Itch

End point description:

SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Subjective symptoms (ie, itch and sleep loss) are each scored by the subject using a VAS where "0" is no itch (or no sleep loss) and "10" is the worst imaginable itch (or sleep loss). The value for each should reflect the average on a 10 point scale for the last 3 days/nights. Change from baseline in SCORAD subjective assessments of itch was not evaluated. Only change from baseline in SCORAD subjective assessments of sleep loss is present below.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	93	96	
Units: Units on a scale				
least squares mean (confidence interval 95%)				
Sleep loss, Week 2	-2.1 (-2.6 to -1.6)	-2.6 (-3.1 to -2.1)	-0.9 (-1.4 to -0.4)	
Sleep loss, Week 4	-2.9 (-3.3 to -2.4)	-3.4 (-3.9 to -2.9)	-1.8 (-2.3 to -1.3)	
Sleep loss, Week 8	-3.3 (-3.8 to -2.9)	-3.7 (-4.2 to -3.2)	-2.2 (-2.7 to -1.7)	
Sleep loss, Week 12	-3.5 (-3.9 to -3.0)	-3.9 (-4.4 to -3.4)	-2.7 (-3.2 to -2.2)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change from Baseline in SCORAD Subjective VAS of Sleep Loss and Itch

End point title	Percent Change from Baseline in SCORAD Subjective VAS of Sleep Loss and Itch

End point description:

SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Subjective symptoms (ie, itch and sleep loss) are each scored by the subject using a VAS where "0" is no itch (or no sleep loss) and "10" is the worst imaginable itch (or sleep loss). The value for each should reflect the average on a 10 point scale for the last 3 days/nights. Change from baseline in SCORAD subjective assessments of itch was not evaluated. Only change from baseline in SCORAD subjective assessments of sleep loss is present below.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	93	96	
Units: Percent change				
least squares mean (confidence interval 95%)				
Sleep loss, Week 2	65.1 (-39.2 to 169.4)	-36.5 (-140.7 to 67.8)	2.6 (-101.2 to 106.3)	
Sleep loss, Week 4	-35.2 (-50.7 to -19.8)	-53.4 (-69.1 to -37.8)	-20.0 (-35.2 to -4.9)	
Sleep loss, Week 8	-44.2 (-79.9 to -8.5)	-30.6 (-66.7 to 5.5)	-24.7 (-60.1 to 10.8)	
Sleep loss, Week 12	-49.8 (-88.3 to -11.3)	-35.2 (-74.1 to 3.7)	-39.5 (-77.7 to -1.3)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Days When a Corticosteroid Not Used up to Day 88

End point title	Number of Days When a Corticosteroid Not Used up to Day 88

End point description:

The analysis include all randomized subjects who received at least one dose of study medication and had used corticosteroid during treatment period

End point type	Secondary

End point timeframe:

Baseline to Day 88

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	89	82	83	
Units: Days				
least squares mean (confidence interval 95%)	10.9 (6.2 to 15.5)	15.1 (10.2 to 19.9)	6.8 (2.0 to 11.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Children's Dermatology Life Quality Index (DLQI)

End point title	Change from Baseline in Children's Dermatology Life Quality Index (DLQI)

End point description:

The DLQI is a general dermatology questionnaire that consists of 10 items to assess subject-reported health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure,

work and school, and treatment).The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 3-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality. Subjects who were withdrew from the study were counted as non-responder. This endpoint's analysis included all randomized subjects who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Units on a scale				
least squares mean (confidence interval 95%)				
Week 2	-6.1 (-7.1 to -5.2)	-6.3 (-7.2 to -5.3)	-4.2 (-5.1 to -3.3)	
Week 4	-7.3 (-8.2 to -6.4)	-7.6 (-8.6 to -6.7)	-5.4 (-6.3 to -4.5)	
Week 8	-8.1 (-9.1 to -7.1)	-8.2 (-9.2 to -7.2)	-6.1 (-7.0 to -5.1)	
Week 12	-8.6 (-9.6 to -7.5)	-8.7 (-9.7 to -7.6)	-6.3 (-7.4 to -5.3)	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects with >=2.5 Points at Baseline and Achieving >=2.5 Points Improvement from Baseline in Children's DLQI

End point title	Proportion of Subjects with >=2.5 Points at Baseline and Achieving >=2.5 Points Improvement from Baseline in Children's DLQI

End point description:

The DLQI is a general dermatology questionnaire that consists of 10 items to assess subject-reported health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). It has been extensively used in clinical trials for AD. The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 3-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality. Subjects who were withdrew from the study were counted as non-responder. The analysis of this endpoint was performed using the FAS which was defined as all randomized subjects who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent of evaluable subjects				
number (confidence interval 95%)				
Week 2	73.6 (64.6 to 82.7)	71.3 (62.1 to 80.4)	61.5 (51.5 to 71.5)	
Week 4	82.4 (74.6 to 90.2)	73.4 (64.5 to 82.3)	73.7 (64.8 to 82.5)	
Week 8	85.9 (78.8 to 93.0)	79.6 (71.4 to 87.8)	71.0 (61.7 to 80.2)	
Week 12	80.9 (72.7 to 89.1)	78.5 (70.1 to 86.8)	67.7 (58.2 to 77.2)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Anxiety of Hospital Anxiety and Depression Scale (HADS)

End point title	Change from Baseline in Anxiety of Hospital Anxiety and Depression Scale (HADS)

End point description:

The HADS is a 14-item patient reported outcome (PRO) measure used to detect states of anxiety and depression over the past week. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome. The analysis of this endpoint was performed using the FAS which was defined as all randomized subjects who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Units on a scale				
least squares mean (confidence interval 95%)				
Week 2	-1.6 (-2.1 to -1.1)	-1.3 (-1.8 to -0.8)	-1.2 (-1.7 to -0.7)	
Week 4	-1.6 (-2.2 to -1.1)	-1.9 (-2.5 to -1.3)	-1.5 (-2.1 to -1.0)	
Week 8	-2.1 (-2.7 to -1.5)	-2.2 (-2.8 to -1.5)	-1.7 (-2.3 to -1.1)	
Week 12	-2.0 (-2.6 to -1.4)	-2.4 (-3.0 to -1.8)	-2.1 (-2.7 to -1.5)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Depression of HADS

End point title	Change from Baseline in Depression of HADS

End point description:

The HADS is a 14-item PRO measure used to detect states of anxiety and depression over the past week. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome. The analysis of this endpoint was performed using the FAS which was defined as all randomized subjects who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Units on a scale				
least squares mean (confidence interval 95%)				
Week 2	-1.2 (-1.7 to -0.8)	-0.8 (-1.3 to -0.3)	-0.8 (-1.3 to -0.3)	
Week 4	-1.3 (-1.8 to -0.8)	-1.3 (-1.8 to -0.8)	-0.8 (-1.3 to -0.3)	
Week 8	-1.4 (-1.9 to -0.9)	-1.2 (-1.7 to -0.7)	-1.1 (-1.6 to -0.6)	
Week 12	-1.4 (-1.9 to -0.8)	-1.2 (-1.7 to -0.6)	-1.0 (-1.5 to -0.5)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Patient-Oriented Eczema Measure (POEM)

End point title	Change from Baseline in Patient-Oriented Eczema Measure (POEM)

End point description:

The POEM is a 7-item PRO measure used to assess the impact of AD over the past week. Each item is scored as "no days (0)", "1-2 days (1)", "3-4 days (2)", "5-6 days (3)" and "every day (4)". The score ranges from 0 to 28. The higher values represent more severe AD. The analysis of this endpoint was performed using the FAS which was defined as all randomized subjects who took at least 1 dose of study

intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	95	
Units: Units on a scale				
least squares mean (confidence interval 95%)				
Week 2	-6.9 (-8.2 to -5.6)	-8.2 (-9.5 to -6.9)	-3.4 (-4.7 to -2.1)	
Week 4	-9.5 (-10.7 to -8.3)	-10.6 (-11.9 to -9.4)	-4.8 (-6.0 to -3.6)	
Week 8	-10.0 (-11.4 to -8.7)	-10.6 (-12.0 to -9.3)	-5.4 (-6.7 to -4.0)	
Week 12	-11.1 (-12.5 to -9.7)	-10.9 (-12.2 to -9.5)	-6.9 (-8.3 to -5.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Dermatitis Family Impact (DFI) at Week 12

End point title	Change from Baseline in Dermatitis Family Impact (DFI) at Week 12

End point description:

The DFI is a validated 10-item measure filled out by the parent/caregiver of the patient used to assess the impact of the patient’s eczema on the family. The instrument has a recall period of 7 days. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse impact. The analysis of this endpoint was performed using the FAS which was defined as all randomized subjects who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	93	92	
Units: Units on a scale				
least squares mean (confidence interval 95%)				
Week 2	-4.2 (-5.2 to -3.1)	-5.2 (-6.2 to -4.1)	-2.7 (-3.7 to -1.6)	

Week 4	-5.7 (-6.7 to -4.6)	-5.9 (-7.0 to -4.9)	-4.8 (-5.8 to -3.7)	
Week 8	-6.8 (-7.9 to -5.7)	-7.3 (-8.5 to -6.2)	-5.1 (-6.3 to -4.0)	
Week 12	-6.7 (-7.9 to -5.4)	-7.3 (-8.6 to -6.0)	-5.2 (-6.5 to -3.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Patient Global Assessment (PtGA)

End point title	Change from Baseline in Patient Global Assessment (PtGA)

End point description:

The PtGA asked the subject to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the Physician's Global Assessment was used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities. The analysis of this endpoint was performed using the FAS which was defined as all randomized subjects who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Units on a scale				
least squares mean (confidence interval 95%)				
Week 2	-0.7 (-0.9 to -0.6)	-1.0 (-1.1 to -0.8)	-0.4 (-0.6 to -0.3)	
Week 4	-0.9 (-1.1 to -0.8)	-1.2 (-1.4 to -1.1)	-0.7 (-0.8 to -0.5)	
Week 8	-1.2 (-1.3 to -1.0)	-1.4 (-1.6 to -1.2)	-0.8 (-1.0 to -0.6)	
Week 12	-1.4 (-1.6 to -1.2)	-1.6 (-1.8 to -1.4)	-0.9 (-1.1 to -0.7)	

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Subjects with >=2 Points at Baseline and Achieving 'Clear' or 'Almost Clear' and >=2 Points Improvement from Baseline in PtGA

End point title	Proportion of Subjects with >=2 Points at Baseline and Achieving 'Clear' or 'Almost Clear' and >=2 Points Improvement from Baseline in PtGA

End point description:

The PtGA asked the subject to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the Physician's Global Assessment was used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities. Subjects who were withdrew from the study were counted as non-responder. The analysis of this endpoint was performed using the FAS which was defined as all randomized subjects who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Percent of evaluable subjects				
number (confidence interval 95%)				
Week 2	5.4 (0.8 to 10.1)	5.3 (0.8 to 9.9)	1.1 (0.0 to 3.2)	
Week 4	14.1 (7.0 to 21.2)	20.2 (12.1 to 28.3)	4.2 (0.2 to 8.2)	
Week 8	22.6 (14.1 to 31.1)	26.9 (17.9 to 35.9)	6.4 (1.4 to 11.3)	
Week 12	30.0 (20.5 to 39.5)	36.6 (26.8 to 46.3)	10.6 (4.4 to 16.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in EuroQol Quality of Life 5-Dimension Youth Scale (EQ-5D-Y) VAS Score

End point title	Change from Baseline in EuroQol Quality of Life 5-Dimension Youth Scale (EQ-5D-Y) VAS Score

End point description:

The EQ-5D is a validated, standardized, generic instrument that is the most widely used preference based health related quality of life questionnaire in cost effectiveness and health technologies assessment. The EQ-5D-Y is a version of the instrument specifically developed and validated for use by youths aged 12 through 17 years. Components assess level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. Score scale ranges from 1 (minimum) to 3 (maximum). Higher scores indicates worse health condition. The analysis of this endpoint was performed using the FAS which was defined as all randomized subjects who took at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Units on a scale				
least squares mean (confidence interval 95%)				
Week 2	11.241 (7.882 to 14.601)	12.141 (8.763 to 15.520)	7.140 (3.787 to 10.492)	
Week 4	13.222 (10.020 to 16.423)	14.677 (11.438 to 17.917)	8.784 (5.625 to 11.943)	
Week 8	14.502 (10.977 to 18.028)	14.653 (11.076 to 18.231)	8.415 (4.888 to 11.941)	
Week 12	14.226 (10.624 to 17.828)	15.756 (12.153 to 19.360)	9.944 (6.373 to 13.515)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Pediatric Functional Assessment of Chronic Illness Therapy Fatigue Scale (Peds-FACIT-F)

End point title	Change from Baseline in Pediatric Functional Assessment of Chronic Illness Therapy Fatigue Scale (Peds-FACIT-F)

End point description:

The Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT–F) is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (none of the time) to 4 (all of the time). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-F score for a total possible score of 0 (worse score) to 52 (better score), with higher scores representing better overall health status (less fatigue). The analysis of this endpoint was performed using the FAS which was defined as all randomized subjects who took at least 1 dose of study intervention. Change from baseline at Week 12 is present below. Change from baseline at other scheduled time points were not evaluated.

End point type	Secondary

End point timeframe:

Baseline to Week 12

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Units on a scale				
least squares mean (confidence interval 95%)	4.5 (3.0 to 5.9)	4.3 (2.9 to 5.7)	2.5 (1.1 to 3.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs)

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAEs)

End point description:

An adverse event (AE) was any untoward medical occurrence in a clinical investigation subject administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator. The safety analysis population included all subjects who received at least 1 dose of study medication.

End point type	Secondary

End point timeframe:

16 Weeks

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Subjects				
All-causality AEs	54	59	50	
Treatment-related AEs	20	31	16	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Serious Adverse Events (SAEs)

End point title	Number of Subjects With Serious Adverse Events (SAEs)

End point description:

A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect.Treatment-related SAEs were determined by the investigator. The safety analysis population included all subjects who received at least 1 dose of study medication.

End point type	Secondary

End point timeframe:

16 weeks

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Subjects				
All-causality SAEs	0	1	2	
Treatment-related SAEs	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects Who Discontinued From the Study Due to TEAEs

End point title	Number of Subjects Who Discontinued From the Study Due to TEAEs

End point description:

An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator. The safety analysis population included all subjects who received at least 1 dose of study medication.

End point type	Secondary

End point timeframe:

16 Weeks

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	96	
Units: Subjects				
All-causality TEAEs	1	2	2	
Treatment-related TEAEs	0	2	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Laboratory Test Abnormalities (Without Regard to Baseline)

End point title	Number of Subjects With Laboratory Test Abnormalities (Without Regard to Baseline)

End point description:

Laboratory tests included hematology (including coagulation panel), chemistry, lipid profiles, and urinalysis. The safety analysis population included all subjects who received at least 1 dose of study medication. LLN is lower limit of normal, ULN is upper limit of normal..

End point type	Secondary

End point timeframe:
16 weeks

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	93	96	
Units: Subjects				
Hb (g/dL) <0.8*LLN	0	0	0	
Hematocrit (%) <0.8*LLN	0	0	0	
Erythrocytes (10^6/mm^3) <0.8*LLN	0	0	0	
Reticulocytes (10^3/mm^3) <0.5*LLN	0	0	0	
Reticulocytes (10^3/mm^3) >1.5*ULN	0	0	0	
Ery. Mean Corpuscular Volume (10^-15L) <0.9*LLN	1	0	1	
Ery. Mean Corpuscular Volume (10^-15L) >1.1*ULN	0	0	0	
Ery. Mean Corpuscular Hb (pg/cell) <0.9*LLN	1	0	1	
Ery. Mean Corpuscular Hb (pg/cell) >1.1*ULN	0	0	0	
Ery. Mean Corpuscular Hb Conc. (g/dL) <0.9*LLN	0	0	0	
Ery. Mean Corpuscular Hb Conc. (g/dL)>1.1*ULN	0	0	0	
Platelets (10^3/mm^3) <0.5*LLN	0	0	1	
Platelets (10^3/mm^3) >1.75*ULN	0	0	0	
Reticulocytes/Erythrocytes (%) <0.5*LLN	0	0	0	
Reticulocytes/Erythrocytes (%) >1.5*ULN	0	1	0	
Leukocytes (10^3/mm^3) <0.6*LLN	0	0	0	
Leukocytes (10^3/mm^3) >1.5*ULN	0	0	1	
Lymphocytes (10^3/mm^3) <0.8*LLN	0	1	0	
Lymphocytes (10^3/mm^3) >1.2*ULN	0	1	0	
Lymphocytes/Leukocytes (%) <0.8*LLN	4	6	6	
Lymphocytes/Leukocytes (%)>1.2*ULN	1	4	1	
Neutrophils (10^3/mm^3) <0.8*LLN	2	1	1	
Neutrophils (10^3/mm^3) >1.2*ULN	5	3	6	
Neutrophils/Leukocytes (%) <0.8*LLN	3	7	5	
Neutrophils/Leukocytes (%) >1.2*ULN	0	0	0	
Basophils (10^3/mm^3) >1.2*ULN	0	0	3	
Basophils/Leukocytes (%) >1.2*ULN	24	27	35	
Eosinophils (10^3/mm^3) >1.2*ULN	55	39	63	
Eosinophils/Leukocytes (%) >1.2*ULN	62	47	61	
Monocytes (10^3/mm^3)>1.2*ULN	0	0	1	
Monocytes/Leukocytes (%) >1.2*ULN	11	6	7	
Partial Thromboplastin Time (sec) >1.1*ULN	4	4	2	
Prothrombin Time (sec) >1.1*ULN	6	8	4	
Prothrombin Intl. Normalized Ratio >1.1*ULN	0	0	0	
Bilirubin (mg/dL) >1.5*ULN	4	0	1	

Direct Bilirubin (mg/dL) >1.5*ULN	0	0	0	
Indirect Bilirubin (mg/dL) >1.5*ULN	2	0	1	
Aspartate Aminotransferase (U/L) >3.0*ULN	1	3	1	
Alanine Aminotransferase (U/L) >3.0*ULN	3	1	0	
Gamma Glutamyl Transferase(U/L) >3.0*ULN	0	0	1	
Lactate Dehydrogenase (U/L) >3.0*ULN	1	2	0	
Alkaline Phosphatase (U/L) >3.0*ULN	0	1	0	
Protein (g/dL) <0.8*LLN	0	0	0	
Protein (g/dL) >1.2*ULN	0	1	0	
Albumin (g/dL) <0.8*LLN	0	0	0	
Albumin (g/dL) >1.2*ULN	0	3	0	
Urea Nitrogen (mg/dL) >1.3*ULN	0	0	0	
Creatine (mg/dL) >1.3*ULN	2	0	3	
Urate (mg/dL) >1.2*ULN	4	1	2	
LDL Cholesterol (mg/dL) >1.2*ULN	2	3	2	
Triglycerides (mg/dL) >1.3*ULN	11	13	17	
Sodium (mEq/L) <0.95*LLN	0	0	0	
Sodium (mEq/L) >1.05*ULN	0	0	0	
Potassium (mEq/L) <0.9*LLN	0	0	0	
Potassium (mEq/L)>1.1*ULN	0	0	1	
Chloride (mEq/L) <0.9*LLN	0	0	0	
Chloride (mEq/L) >1.1*ULN	0	0	0	
Calcium (mEq/L) <0.9*LLN	0	0	0	
Calcium (mEq/L) >1.1*ULN	0	0	0	
Bicarbonate (mEq/L) <0.9*LLN	1	0	1	
Bicarbonate (mEq/L) >1.1*ULN	0	0	0	
Glucose (mg/dL) <0.6*LLN	0	0	0	
Glucose (mg/dL) >1.5*ULN	2	3	0	
Creatine Kinase (U/L) >2.0*ULN	7	12	5	
Cholesterol (mg/dL) >1.3*ULN	2	2	2	
HDL Cholesterol (mg/dL) <0.8*LLN	0	0	0	
Urine Specific Gravity (scalar) <1.003	0	0	0	
Urine Specific Gravity (scalar) >1.030	1	0	0	
Urine pH (scalar) <4.5	0	0	0	
Urine pH (scalar) >8	1	0	0	
Urine Glucose >=1	0	0	1	
Urine Ketones >=1	0	1	8	
Urine Protein >=1	5	0	4	
Urine Hemoglobin >=1	19	15	20	
Urine Nitrite >=1	1	0	0	
Urine Leukocyte Esterase >=1	14	17	7	
Urine Erythrocytes (/HPF) >=20	7	5	8	
Urine Leukocytes (/HPF) >=20	2	1	0	
Granular Casts (/LPF) >1	0	0	1	
Hyaline Casts (/LPF) >1	1	1	2	
Urine Bacteria >20	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subject with Electrocardiogram (ECG) Data Meeting Pre-specified Criteria

End point title	Number of Subject with Electrocardiogram (ECG) Data Meeting Pre-specified Criteria

End point description:

A 12-lead ECG was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT intervals. All scheduled ECGs were performed after the subject had rested quietly for at least 10 minutes in a supine position. The endpoint's analysis included all subjects who received at least 1 dose of study medication.

End point type	Secondary

End point timeframe:

16 Weeks

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	93	96	
Units: Subjects				
QTcF interval>500 msec	0	0	0	
Change from Screening in QTcF >60 msec	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Categoriztion of Vital Signs Data Meeting Prespecified Criteria

End point title	Categoriztion of Vital Signs Data Meeting Prespecified Criteria

End point description:

Vital signs (pulse rate, systolic and diastolic blood pressure [BP]) were obtained with subject in the seated position, after having sat calmly for at least 5 minutes. The endpoint's analysis included all subjects who received at least 1 dose of study medication.

End point type	Secondary

End point timeframe:

16 weeks

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	93	96	
Units: Subjects				
Diastolic BP <50 mmHg	1	9	3	
Diastolic BR increase from baseline >= 20 mmHg	6	6	3	
Diastolic BR decrease from baseline >= 20 mmHg	4	8	3	
Pulse Rate <40 bpm	0	0	0	
Pulse Rate >120 bpm	0	0	0	
Systolic BP <90 mmHg	7	4	4	
Systolic BR increase from baseline >= 30 mmHg	1	2	2	
Systolic BR decrease from baseline >= 30 mmHg	1	2	2	

Statistical analyses

No statistical analyses for this end point

Secondary: Fold Increase of Immunoglobulin G (IgG) Concentrations against Specific Vaccine Antigens at 4 Weeks Post-Vaccination

End point title	Fold Increase of Immunoglobulin G (IgG) Concentrations against Specific Vaccine Antigens at 4 Weeks Post-Vaccination

End point description:

The immunogenicity analysis was to evaluate the effect of abrocitinib on immunogenicity to a tetanus, diphtheria and pertussis combination vaccine (Tdap) vaccine in adolescent subjects 12 to <18 years of age with moderate to severe AD. Subjects who completed 8 weeks of treatment with study intervention received Tdap at Week 8, and had blood samples collected for the evaluation of immunogenicity to the vaccine at Weeks 8 and 12. Immunogenicity analysis set was defined as subjects who had completed 8 weeks of treatment and after Tdap vaccination. The fold increase was defined as the ratio (post-vaccination: pre-vaccination) of concentration values. The geometric mean fold rise (GMFR) is presented below and it was calculated by first arithmetically averaging the logarithmically transformed ratio (post-vaccination: pre-vaccination) values, and then back transformation.

End point type	Secondary

End point timeframe:

4 weeks

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	6	10	
Units: Ratio				
geometric mean (confidence interval 95%)				
Diphtheria IgG Antibody	6.51 (2.31 to 18.34)	34.61 (6.96 to 172.06)	14.00 (6.32 to 30.99)	
Filamentous Hemagglutinin IgG	11.48 (2.65 to 49.69)	22.77 (7.26 to 71.45)	15.19 (4.89 to 47.16)	

Fimbriae 2/3 IgG	1.11 (0.85 to 1.46)	1.47 (0.61 to 3.50)	1.93 (0.79 to 4.73)	
Pertactin IgG	15.60 (5.77 to 42.14)	60.18 (12.79 to 283.08)	54.03 (14.67 to 199.03)	
Pertussis Toxin IgG	10.17 (4.71 to 21.94)	33.16 (5.04 to 218.38)	6.94 (1.95 to 24.71)	
Tetanus Toxoid IgG Antibody	16.26 (3.52 to 75.11)	48.41 (9.01 to 260.09)	8.36 (1.62 to 43.18)	

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma PF-04965842 Concentration at Week 8

End point title	Plasma PF-04965842 Concentration at Week 8[25]

End point description:

End point type	Secondary

End point timeframe:

2 hours before Week 8 visit dose

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	62		
Units: ng/mL				
arithmetic mean (standard deviation)	7.882 (± 26.350)	32.33 (± 76.506)		

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma PF-04965842 Concentration at Week 12

End point title	Plasma PF-04965842 Concentration at Week 12[26]

End point description:

End point type	Secondary

End point timeframe:

2 hours post Week 12 visit dosing

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	PF-04965842 100mg QD	PF-04965842 200mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	59	50		
Units: ng/mL				
arithmetic mean (standard deviation)	486.6 (± 403.69)	1271 (± 1000.4)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

16 weeks

Adverse event reporting additional description:

The same event may appear as both an AE and an SAE. An event may be categorized as serious in one subject and as non-serious in another subject, or one subject may have experienced both a serious and non-serious event during the study. Total number at risk below refers to the number of subjects evaluable for SAEs or AEs.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	23.0

Reporting groups

Reporting group title	PF-04965842 100 mg QD
Reporting group description: -	
Reporting group title	PF-04965842 200 mg QD
Reporting group description: -	
Reporting group title	Placebo

Reporting group description: -

Serious adverse events	PF-04965842 100 mg QD	PF-04965842 200 mg QD	Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 95 (0.00%)	1 / 94 (1.06%)	2 / 96 (2.08%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 95 (0.00%)	0 / 94 (0.00%)	1 / 96 (1.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis atopic			
subjects affected / exposed	0 / 95 (0.00%)	0 / 94 (0.00%)	1 / 96 (1.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Anxiety			

subjects affected / exposed	0 / 95 (0.00%)	1 / 94 (1.06%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	PF-04965842 100 mg QD	PF-04965842 200 mg QD	Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	54 / 95 (56.84%)	59 / 94 (62.77%)	49 / 96 (51.04%)
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	4 / 95 (4.21%)	4 / 94 (4.26%)	0 / 96 (0.00%)
occurrences (all)	5	4	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 95 (1.05%)	2 / 94 (2.13%)	0 / 96 (0.00%)
occurrences (all)	1	2	0
Blood uric acid increased			
subjects affected / exposed	1 / 95 (1.05%)	0 / 94 (0.00%)	2 / 96 (2.08%)
occurrences (all)	1	0	2
Haemoglobin increased			
subjects affected / exposed	0 / 95 (0.00%)	2 / 94 (2.13%)	0 / 96 (0.00%)
occurrences (all)	0	3	0
Protein urine			
subjects affected / exposed	1 / 95 (1.05%)	0 / 94 (0.00%)	2 / 96 (2.08%)
occurrences (all)	1	0	2
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	2 / 95 (2.11%)	0 / 94 (0.00%)	0 / 96 (0.00%)
occurrences (all)	2	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 95 (0.00%)	6 / 94 (6.38%)	1 / 96 (1.04%)
occurrences (all)	0	9	2
Headache			

subjects affected / exposed	5 / 95 (5.26%)	8 / 94 (8.51%)	7 / 96 (7.29%)
occurrences (all)	7	12	8
Somnolence			
subjects affected / exposed	0 / 95 (0.00%)	2 / 94 (2.13%)	2 / 96 (2.08%)
occurrences (all)	0	2	2
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 95 (2.11%)	0 / 94 (0.00%)	1 / 96 (1.04%)
occurrences (all)	2	0	1
Pyrexia			
subjects affected / exposed	3 / 95 (3.16%)	1 / 94 (1.06%)	4 / 96 (4.17%)
occurrences (all)	3	1	4
Blood and lymphatic system disorders			
Eosinophilia			
subjects affected / exposed	0 / 95 (0.00%)	0 / 94 (0.00%)	2 / 96 (2.08%)
occurrences (all)	0	0	2
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 95 (1.05%)	3 / 94 (3.19%)	1 / 96 (1.04%)
occurrences (all)	1	3	1
Diarrhoea			
subjects affected / exposed	2 / 95 (2.11%)	1 / 94 (1.06%)	0 / 96 (0.00%)
occurrences (all)	2	1	0
Lip swelling			
subjects affected / exposed	0 / 95 (0.00%)	0 / 94 (0.00%)	2 / 96 (2.08%)
occurrences (all)	0	0	2
Nausea			
subjects affected / exposed	7 / 95 (7.37%)	17 / 94 (18.09%)	1 / 96 (1.04%)
occurrences (all)	7	27	2
Abdominal pain upper			
subjects affected / exposed	0 / 95 (0.00%)	4 / 94 (4.26%)	0 / 96 (0.00%)
occurrences (all)	0	5	0
Vomiting			
subjects affected / exposed	4 / 95 (4.21%)	5 / 94 (5.32%)	0 / 96 (0.00%)
occurrences (all)	4	7	0
Respiratory, thoracic and mediastinal disorders			

Asthma			
subjects affected / exposed	1 / 95 (1.05%)	1 / 94 (1.06%)	2 / 96 (2.08%)
occurrences (all)	1	3	2
Cough			
subjects affected / exposed	4 / 95 (4.21%)	1 / 94 (1.06%)	2 / 96 (2.08%)
occurrences (all)	6	1	2
Rhinorrhoea			
subjects affected / exposed	1 / 95 (1.05%)	0 / 94 (0.00%)	3 / 96 (3.13%)
occurrences (all)	1	0	4
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	3 / 95 (3.16%)	5 / 94 (5.32%)	1 / 96 (1.04%)
occurrences (all)	3	5	2
Dermatitis atopic			
subjects affected / exposed	2 / 95 (2.11%)	1 / 94 (1.06%)	2 / 96 (2.08%)
occurrences (all)	2	2	2
Infections and infestations			
Folliculitis			
subjects affected / exposed	7 / 95 (7.37%)	2 / 94 (2.13%)	1 / 96 (1.04%)
occurrences (all)	7	2	1
Gastroenteritis			
subjects affected / exposed	2 / 95 (2.11%)	2 / 94 (2.13%)	1 / 96 (1.04%)
occurrences (all)	2	2	1
Hordeolum			
subjects affected / exposed	2 / 95 (2.11%)	0 / 94 (0.00%)	0 / 96 (0.00%)
occurrences (all)	2	0	0
Influenza			
subjects affected / exposed	4 / 95 (4.21%)	2 / 94 (2.13%)	1 / 96 (1.04%)
occurrences (all)	4	2	1
Nasopharyngitis			
subjects affected / exposed	8 / 95 (8.42%)	8 / 94 (8.51%)	9 / 96 (9.38%)
occurrences (all)	10	9	11
Oral herpes			
subjects affected / exposed	1 / 95 (1.05%)	2 / 94 (2.13%)	0 / 96 (0.00%)
occurrences (all)	2	2	0
Pharyngitis			

subjects affected / exposed	5 / 95 (5.26%)	3 / 94 (3.19%)	3 / 96 (3.13%)
occurrences (all)	5	3	3
Pharyngitis streptococcal			
subjects affected / exposed	0 / 95 (0.00%)	0 / 94 (0.00%)	2 / 96 (2.08%)
occurrences (all)	0	0	2
Sinusitis			
subjects affected / exposed	0 / 95 (0.00%)	3 / 94 (3.19%)	0 / 96 (0.00%)
occurrences (all)	0	3	0
Upper respiratory tract infection			
subjects affected / exposed	9 / 95 (9.47%)	10 / 94 (10.64%)	10 / 96 (10.42%)
occurrences (all)	11	14	12

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported